At IRBM, our experience in the development of custom assays is leveraged into a robust, efficient and multi-parameter validation platform to confirm the biological and pathological role of your novel target. The data package generated by our team can then be transferred seamlessly forward for Hit Identification.
- In vitro and In vivo gene knock-out and over-expression studies;
- Expression profiling in relevant proprietary or commercially available cell lines;
- Development and deployment of bioassays to measure biological activity and characterize the pharmacology of the target;
- Target deconvolution.